ORCHESTRA BIOMED HOLDINGS INC.
NASDAQ: OBIO (Orchestra BioMed Holdings, Inc.)
最近更新时间: 46分钟之前6.97
-0.15 (-2.11%)
新闻情绪
-
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
2天之前, 7:55AM
-
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
10 Nov, 3:10PM
-
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
10 Nov, 4:40PM
-
Orchestra BioMed Announces Pricing of Public Offering
05 Nov, 9:42PM
-
Orchestra BioMed Announces Proposed Public Offering
05 Nov, 3:01PM
AIStockmoo 评分
| 价值 30% | -3.1 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 时机 30% | 3.4 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈上升趋势。股价接近52周高点。 参考 | |
| 股价与均线呈多头排列。主要均线走平。接近上升的均线。上涨日成交量较大。 参考 | |
| K线形态 参考 | NA |
| 高于中期趋势线。 参考 | |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | 3.0 |
| 多名内部人士近期净买入。 参考 | |
| 机构在最新13F申报中净+5.72%的股份:61家增持,31家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+11.0%,回补天数7天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价高于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向上。短期动能上升。 参考 | |
| 支撑与阻力没有明确信号。 参考 | |
| 最终评分 | 0.53 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Orchestra BioMed Holdings, Inc. | 混合的 | 看跌 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| OBIO | - | - | - | 57.25 |
| TRML | 1 B | - | - | 4.76 |
| VRDN | - | - | - | 7.26 |
| VRCA | - | - | - | 15.60 |
| TECH | - | 0.44% | - | 5.28 |
| ABEO | - | - | - | 1.10 |
|
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 21.81% |
| 机构持股比例 | 49.62% |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FAIN ERIC S | 5.70 | - | 20,000 | 114,000 |
| HOCHMAN DAVID P | 5.70 | - | 5,000 | 28,500 |
| PACITTI DAVID | 5.70 | - | 20,000 | 114,000 |
| TAYLOR ANDREW LAWRENCE | 5.70 | - | 1,000 | 5,700 |
| 累积净数量 | 46,000 | |||
| 累积净值 ($) | 262,200 | |||
| 累积平均购买 ($) | 5.70 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| TAYLOR ANDREW LAWRENCE | 职员 | 09 Nov 2026 | 买 (+) | 1,000 | 5.70 | 5,700 |
| HOCHMAN DAVID P | 职员 | 09 Nov 2026 | 买 (+) | 5,000 | 5.70 | 28,500 |
| PACITTI DAVID | 董事 | 09 Nov 2026 | 买 (+) | 20,000 | 5.70 | 114,000 |
| FAIN ERIC S | 董事 | 09 Nov 2026 | 买 (+) | 20,000 | 5.70 | 114,000 |
机构
机构持股比例: 41.73%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 61 | 5,034,559 |
| 减持 | 31 | 1,386,397 |
| 新建仓 | 27 | 1,437,879 |
| 清仓 | 11 | 569,836 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 2,732,484 | 7.0 |
| 15 Oct 2026 | 2,552,988 | 9.7 |
| 30 Sep 2026 | 2,547,249 | 7.0 |
| 15 Sep 2026 | 2,372,557 | 6.6 |
| 31 Aug 2026 | 2,460,669 | 5.8 |
| 14 Aug 2026 | 2,383,854 | 13.1 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 16 Nov 2026 | Yahoo Finance |
Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 10 Nov 2026 | Yahoo Finance |
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 10 Nov 2026 | Yahoo Finance |
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).Medtronic… |
| 05 Nov 2026 | Yahoo Finance |
Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 05 Nov 2026 | Yahoo Finance |
Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device… |
| 29 Oct 2026 | Yahoo Finance |
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels… |
| 22 Oct 2026 | Yahoo Finance |
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq… |
| 20 Oct 2026 | Yahoo Finance |
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday . |
| 01 Oct 2026 | Yahoo Finance |
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing… |
| 21 Sep 2026 | Yahoo Finance |
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
| 16 Sep 2026 | Yahoo Finance |
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO)… |
| 15 Sep 2026 | Yahoo Finance |
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides… |
| 02 Sep 2026 | Yahoo Finance |
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported… |
| 27 Aug 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman… |
| 20 Aug 2026 | Yahoo Finance |
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合